Tag: Pharmaceutical Innovation Award

Vibhu Sahani | Pharmacology | Lifetime Achievement Award

Published on by World Science Awards

Lifetime Achievement Award

Vibhu Sahani
LLRM Medical College, Meerut
Vibhu Sahani
Affiliation LLRM Medical College, Meerut
Country India
Scopus ID 59031594100
Documents 7
Citations 8
h-index 1
Subject Area Pharmacology
Event World Science Awards

The Lifetime Achievement Award recognizes sustained academic service, scholarly engagement, and professional contributions within a scientific discipline. Vibhu Sahani of LLRM Medical College, Meerut has contributed to the field of pharmacology through research, scholarly publication, and academic activities. The available bibliometric information indicates participation in peer-reviewed scientific communication and ongoing involvement in pharmacological research.[1]

Abstract

Vibhu Sahani is an academic associated with LLRM Medical College, Meerut, India, whose scholarly work is focused on pharmacology. His published research contributes to the understanding of pharmacological science and supports continued advancement in medical research. Available bibliometric indicators, including indexed publications and citations, reflect participation in the international scientific literature and ongoing academic engagement.[1][2]

Keywords

  • Pharmacology
  • Drug Research
  • Medical Science
  • Clinical Pharmacology
  • Biomedical Research
  • Scientific Publications
  • Research Impact
  • World Science Awards

Introduction

Pharmacology is a multidisciplinary scientific field dedicated to understanding the mechanisms, therapeutic applications, efficacy, and safety of medicinal compounds. Research in pharmacology contributes significantly to disease prevention, treatment innovation, and evidence-based healthcare. Academic researchers working in this discipline support advances through laboratory investigations, clinical studies, and scientific publication.[3]

Research Profile

Based on the available Scopus data, Vibhu Sahani has authored seven indexed documents, received eight citations, and holds an h-index of one. These bibliometric indicators demonstrate participation in scholarly research and publication within pharmacology while contributing to the scientific literature through peer-reviewed academic work.[1]

  • Affiliation with LLRM Medical College, Meerut.
  • Primary research area: Pharmacology.
  • Indexed scientific publications: 7.
  • Total citations: 8.
  • Scopus h-index: 1.

Research Contributions

The available publication record indicates contributions to pharmacological investigations and medical science. Research activities in this field support the understanding of therapeutic interventions, drug action, patient care, and evidence-based medicine. Such scholarly contributions form an important part of continued scientific development in healthcare disciplines.[2][3]

Publications

The researcher’s publication portfolio includes peer-reviewed scientific articles indexed within international scholarly databases. These publications demonstrate participation in academic research and dissemination of scientific findings relevant to pharmacology and associated biomedical disciplines.[1]

  • Peer-reviewed journal publications.
  • Pharmacological and biomedical research.
  • Scientific collaboration and academic dissemination.
  • Indexed scholarly contributions.

Research Impact

Research impact is commonly evaluated through publication output, citation performance, scholarly visibility, and contribution to scientific knowledge. The available metrics indicate that Vibhu Sahani has established an indexed research presence in pharmacology. These bibliometric indicators provide objective evidence of participation in scholarly communication while supporting continued academic development.[1]

Award Suitability

Based on the information provided, Vibhu Sahani demonstrates academic engagement through research publication, institutional affiliation, and contributions to pharmacology. Consideration for recognition within the World Science Awards may acknowledge sustained scholarly participation and professional service. Final award decisions should be based on the complete evaluation criteria established by the organizing committee, including academic achievements, research quality, professional experience, and broader scientific contributions.[1][2]

Conclusion

Vibhu Sahani has contributed to pharmacological research through scholarly publication and academic engagement at LLRM Medical College, Meerut. His indexed research record reflects participation in scientific communication and supports ongoing advancement within the biomedical sciences. The documented academic profile provides an objective overview of research activity relevant to professional recognition in the scientific community.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Vibhu Sahani, Author ID 59031594100. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=59031594100
  2. World Science Awards. (n.d.). Recognition of scientific excellence through international academic awards.
    https://worldscienceawards.com/
  3. Goodman & Gilman’s. The Pharmacological Basis of Therapeutics.
  4. Nature Reviews Drug Discovery. Drug discovery and pharmacological innovation.
    DOI: https://doi.org/10.1038/nrd.2017.232

Ved Pal | Pharmacology | Innovative Research Award

Published on by World Science Awards

Innovative Research Award

Ved Pal
Affiliation ISF College of Pharmacy, Moga, Punjab
Country India
Scopus ID 59895257200
Documents 3
Citations 5
h-index 1
Subject Area Pharmacology
Event World Science Awards
ORCID 0000-0003-3523-1469

Ved Pal
ISF College of Pharmacy, Moga, Punjab, India

The Innovative Research Award recognizes researchers whose scholarly activities demonstrate sustained commitment to scientific advancement, innovation, and academic excellence. VED PAL, affiliated with ISF College of Pharmacy, Moga, Punjab, has established an academic profile in the field of pharmacology through research contributions, professional engagement, and participation in internationally recognized scholarly platforms.[1]

Abstract

VED PAL is an academic researcher associated with ISF College of Pharmacy, Moga, Punjab, India. His scholarly interests are centered on pharmacology, an interdisciplinary field that integrates pharmaceutical sciences, biomedical research, and therapeutic innovation. His academic profile reflects ongoing engagement with scientific publication, research dissemination, and professional development within the pharmaceutical sciences.[1][2]

Keywords

Pharmacology, Pharmaceutical Sciences, Drug Research, Biomedical Science, Therapeutics, Academic Research, Scientific Publications, Innovation, World Science Awards, Healthcare Research.

Introduction

Pharmacology remains one of the most significant scientific disciplines supporting healthcare innovation through the study of medicines, therapeutic mechanisms, and biological responses. Researchers working in this field contribute toward improving evidence-based healthcare, advancing pharmaceutical technologies, and supporting interdisciplinary scientific collaboration. Academic recognition programs acknowledge these contributions by evaluating research quality, scholarly productivity, and scientific impact using internationally recognized academic indicators.[2][3]

Research Profile

VED PAL is affiliated with ISF College of Pharmacy in Punjab, India, where his academic interests align with pharmacological research and pharmaceutical sciences. His scholarly identity is represented through internationally recognized researcher identifiers, including a Scopus Author ID and an ORCID profile, supporting transparency in research attribution and academic visibility.[1][4]

Research Contributions

Research activities in pharmacology typically involve investigations related to drug discovery, therapeutic evaluation, pharmacodynamics, pharmacokinetics, toxicology, and clinical relevance. Through academic participation and publication activities, VED PAL contributes to the broader scientific dialogue supporting pharmaceutical research and evidence-driven healthcare. Such contributions encourage collaboration between academic institutions and the scientific community while promoting responsible research practices.[2][5]

Publications

The researcher’s scholarly output is indexed through the Scopus author profile associated with Author ID 59895257200. Publication records, citation data, and bibliographic information are maintained through recognized academic indexing systems, allowing researchers and institutions to monitor scientific productivity and collaboration.[1]

Research Impact

Research impact extends beyond publication volume and includes scientific influence, collaboration, knowledge dissemination, and practical application of research findings. International researcher identifiers such as ORCID and Scopus improve research discoverability, strengthen scholarly communication, and facilitate accurate attribution across academic databases. These systems support transparent evaluation of academic achievements within the global research ecosystem.[1][4]

Award Suitability

The Innovative Research Award recognizes researchers demonstrating commitment to scholarly excellence, ethical research practices, scientific innovation, and meaningful contributions within their discipline. Based on the available academic identifiers, institutional affiliation, and specialization in pharmacology, VED PAL represents a researcher whose profile aligns with the objectives of recognizing ongoing scientific engagement and academic development through the World Science Awards.[5]

Conclusion

VED PAL’s academic profile reflects continued participation in pharmaceutical research and international scholarly communication. Through institutional affiliation, recognized researcher identifiers, and engagement with pharmacological sciences, the profile illustrates a commitment to research integrity, scientific advancement, and professional development. Recognition through the Innovative Research Award highlights the importance of sustained contributions to contemporary scientific research while encouraging future innovation within the pharmaceutical sciences.[1][5]

References

  1. Elsevier. (n.d.). Scopus Author Details: VED PAL, Author ID 59895257200. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=59895257200
  2. Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (2023). Goodman & Gilman’s The Pharmacological Basis of Therapeutics.
    DOI: https://doi.org/10.1038/s41573-021-00234-4
  3. World Health Organization. (n.d.). Research for Health.
    https://www.who.int
  4. ORCID. (n.d.). ORCID Record: 0000-0003-3523-1469.
    https://orcid.org/0000-0003-3523-1469
  5. World Science Awards. (n.d.). Award Evaluation and Recognition Framework.
    https://worldscienceawards.com/

Antra Chaudhary | Pharmaceutical Science | Young Scientist Award

Published on by World Science Awards

Young Scientist Award

Antra Chaudhary,
Jamia Hamdard University, New Delhi, India.

Antra Chaudhary
Affiliation Jamia Hamdard University
Country India
Scopus ID 57406830100
Documents 10
Citations 119
h-index 5
Subject Area Pharmacology, Toxicology and Pharmaceutical Science
Event World Science Awards
ORCID 0009-0006-9003-5566

Antra Chaudhary is an Indian pharmacology researcher and doctoral scholar recognized for her contributions to bone pharmacology, oxidative stress, inflammatory disorders, and neuroprotection research. Her academic work has focused extensively on translational pharmacological approaches involving medicinal plants, osteoporosis therapeutics, neuroinflammation, stem cell-based therapies, and molecular signaling pathways associated with disease progression and tissue protection.[1] She is currently pursuing doctoral research at Jamia Hamdard University under the supervision of Prof. Divya Vohora, where her investigations explore the therapeutic potential of natural compounds against glucocorticoid-induced bone damage and postmenopausal osteoporosis.[2]

Abstract

This academic article presents a scholarly overview of the research contributions, scientific achievements, and professional development of Antra Chaudhary, a pharmacology researcher specializing in bone pharmacology, oxidative stress, inflammatory disorders, and neuroprotection. Her research has contributed to understanding molecular signaling pathways associated with osteoporosis, ischemic stroke, rheumatoid arthritis, and mitochondrial dysfunction. Through interdisciplinary pharmacological investigations involving in vitro and in vivo models, her work has emphasized translational therapeutic strategies and the use of bioactive compounds for disease modulation.[3] The article further documents her academic qualifications, awards, technical expertise, scientific publications, and suitability for academic recognition in the field of pharmacology and biomedical sciences.

Keywords

Bone Pharmacology, Oxidative Stress, Osteoporosis, Pharmacology, Neuroprotection, Medicinal Plants, Inflammatory Diseases, Stem Cell Therapy, Molecular Pharmacology, Translational Research, Rheumatoid Arthritis, Glucocorticoid-Induced Bone Damage, Pharmacodynamics, Biomedical Sciences.

Introduction

Contemporary pharmacological research increasingly emphasizes translational approaches that integrate molecular biology, therapeutic intervention, and clinical applicability. Researchers in pharmacology are actively investigating novel compounds and signaling pathways to address chronic diseases, neurodegeneration, inflammatory disorders, and metabolic dysfunctions.[4] Within this scientific landscape, Antra Chaudhary has contributed to emerging research areas involving osteoporosis therapeutics, oxidative stress modulation, neuroinflammation, and medicinal plant-based pharmacological interventions.

Her academic journey reflects a progression through pharmaceutical sciences and toxicology training, supported by competitive national examinations including GPAT and NIPER-JEE. She has participated in multidisciplinary research projects and advanced laboratory investigations utilizing molecular, histological, and imaging-based techniques for experimental pharmacology studies.[5]

Research Profile

Antra Chaudhary completed her Master of Science in Pharmacology and Toxicology from the National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, where she worked on medicinal plant extracts from North-East India for inflammatory disease research. Her doctoral research at Jamia Hamdard University focuses on bone pharmacology and oxidative stress biology under the supervision of Prof. Divya Vohora.[2]

Her technical expertise encompasses a broad range of experimental methodologies, including Western blotting, RT-PCR, immunohistochemistry, fluorescence microscopy, micro-computed tomography, small animal imaging, and cell culture systems. She has also demonstrated competence in pharmacological data analysis using GraphPad Prism and image analysis software.[3]

  • DST WISE KIRAN Fellow for doctoral research in Life Sciences.
  • Qualified GPAT and NIPER-JEE examinations with competitive national rankings.
  • Recipient of the Young Investigator Award 2025 at IPC-IPSCON 2025.
  • Contributor to peer-reviewed journals in pharmacology and neuroscience.

Research Contributions

The scientific contributions of Antra Chaudhary span multiple pharmacological domains, including neuroprotection, osteoporosis, inflammatory signaling, and mitochondrial biology. Her collaborative studies have investigated the role of cardiolipin-mediated mitochondrial protection in ischemic stroke and the therapeutic implications of stem cell-mediated inflammasome modulation.[1]

Her work on bone-targeted daidzein-loaded hydroxyapatite nanoparticles evaluated osteogenic potential and pharmacodynamic activity in postmenopausal osteoporosis models, highlighting nanotechnology-assisted therapeutic delivery systems.[8] Additionally, she contributed to research exploring TLR4/NF-κB and Keap1/Nrf2 signaling pathways in rheumatoid arthritis using perillyl alcohol interventions.[2]

Her review publications further discuss CRISPR/Cas9 technologies in neurological disorders, drug repurposing strategies for stroke intervention, and glial cell responses in neurodegenerative conditions.[5]

Publications

Selected Research Articles

  1. Gautam N, Sharma P, Chaudhary A, et al. Investigating the osteogenic potential of bone-targeted daidzein loaded hydroxyapatite nanoparticles for postmenopausal osteoporosis. Journal of Drug Targeting, 2025.
  2. Sarmah D, Sarkar A, Datta A, et al. Cardiolipin-mediated alleviation of mitochondrial dysfunction is a neuroprotective effect of statin in ischemic stroke. ACS Chemical Neuroscience, 2023.
  3. Puppala ER, Jain S, Saha P, et al. Perillyl alcohol attenuates rheumatoid arthritis via regulating TLR4/NF-κB and Keap1/Nrf2 signaling pathways. Phytomedicine, 2022.

Review Articles

  • Advancement in CRISPR/Cas9 technology to better understand and treat neurological disorders.
  • Drug repurposing for stroke intervention.
  • Glial cells response in stroke.

Research Impact

The research contributions of Antra Chaudhary demonstrate interdisciplinary relevance across pharmacology, neuroscience, and biomedical sciences. Her publications address clinically significant challenges associated with osteoporosis, ischemic stroke, inflammatory diseases, and oxidative stress-mediated tissue injury.[11]

Her collaborative work in molecular pharmacology and translational therapeutics contributes to ongoing scientific efforts aimed at developing safer and more effective treatment strategies. The integration of medicinal plant research, nanotechnology-based drug delivery systems, and cellular signaling investigations highlights the translational significance of her scientific profile.[2]

Award Suitability

Antra Chaudhary’s academic profile reflects sustained engagement in experimental pharmacology, translational biomedical research, and scientific dissemination through peer-reviewed publications and conference presentations. Her recognition through the Young Investigator Award at IPC-IPSCON 2025 further demonstrates professional acknowledgment of her contributions within the pharmacological research community.[3]

Her expertise in advanced laboratory techniques, coupled with her publication record and participation in international scientific activities, supports her suitability for academic recognition in the field of pharmacology and bone research. The interdisciplinary scope of her work aligns with contemporary priorities in therapeutic innovation and disease prevention.

Conclusion

Antra Chaudhary represents an emerging researcher in pharmacology whose scientific activities encompass bone pharmacology, oxidative stress biology, neuroprotection, and translational therapeutics. Through experimental research, scholarly publications, and active participation in scientific conferences, she has contributed to advancing knowledge in multiple biomedical domains. Her work continues to support the development of innovative therapeutic approaches aimed at improving disease management and bone health outcomes.[1]

References

  1. Jamia Hamdard University. (2026). Doctoral Research Profile of Antra Chaudhary.
  2. Jamia Hamdard University. (2026). Bone Pharmacology and Oxidative Stress Research Program.
  3. Elsevier. (2025). Pharmacological approaches in osteoporosis and translational therapeutics.
  4. Drug Discovery Today. (2022). Drug repurposing for stroke intervention.
    https://doi.org/10.1016/j.drudis.2022.03.014
  5. National Institute of Pharmaceutical Education and Research. (2020). MS Research Project Documentation.

Yan Niu | Pharmaceutical Science | Research Excellence Award

Published on by World Science Awards

Prof. Yan Niu | Pharmaceutical Science | Research Excellence Award

Peking University | China

Prof. Yan Niu is a medicinal chemist at Peking University whose research focuses on the discovery and optimization of biologically active small molecules, with special emphasis on hydrophobic tagging–based targeted protein degradation. She has contributed significant advances in amino-acid–derived hydrophobic tags capable of inducing selective POI degradation with mechanisms and pharmacological profiles distinct from PROTACs, expanding the chemical space available for next-generation degraders. With 47 Scopus-indexed publications, 549 citations, and an h-index of 14, her work bridges synthetic chemistry, chemical biology, and drug discovery. She has led competitive national projects, filed three patents, and collaborated internationally in Germany and Austria. Her research provides promising strategies for developing novel therapeutics and deepens mechanistic understanding of protein degradation pathways, contributing to innovation in medicinal chemistry and early-stage drug development.

Citation Metrics (Scopus)

500
450
300
150
0

Citations
549
Documents
47
h-index
14

Citations

Documents

h-index

Featured Publications

 

Omid Mehrpour | Pharmaceutical Science | Editorial Board Member

Published on by World Science Awards

Dr. Omid Mehrpour | Pharmaceutical Science | Editorial Board Member

Wayne State University | United States

Dr. Omid Mehrpour is a distinguished medical toxicologist, clinical data scientist, and physician whose work integrates toxicology, public health, and artificial intelligence to advance diagnostic accuracy and patient outcomes. With over two decades of academic, clinical, and research experience, he has become an internationally recognized expert in poisoning, substance use disorders, and AI-driven medical decision-making. Dr. Mehrpour has authored more than 200 peer-reviewed articles, ten book chapters, and a book translation, accumulating over 4,000 scientific citations. His publications and research outputs have significantly shaped clinical toxicology guidelines globally, particularly in areas related to opioids, heavy metals, aluminum phosphide, cannabinoids, and environmental toxicants. A pioneer in AI-based diagnostic innovation, Dr. Mehrpour developed machine learning–driven protocols for poison diagnosis, leading to two registered U.S. patents and additional patents in Iran for diagnostic software and toxicology devices. His work at the Rocky Mountain Poison & Drug Safety Center and collaborations with national databases such as NPDS and ToxIC contributed foundational methods for rapid identification and triage of poisoning cases. He has also led AI and clinical informatics initiatives at the University of Colorado Anschutz Medical Campus and founded AI and Health LLC to develop intelligent clinical tools that enhance diagnosis and care delivery. Throughout his career, Dr. Mehrpour has held leadership roles including Head of the Medical Toxicology and Drug Abuse Research Center and Director of the Poisoning Ward at Birjand University of Medical Sciences. He has supervised numerous graduate researchers and served on editorial boards of multiple international journals. His contributions have received global recognition, including placement among the top 2% of scientists worldwide, multiple “Top Reviewer” honors from Publons, and numerous national research awards. Dr. Mehrpour’s work continues to elevate the fields of toxicology, predictive modeling, and precision medicine, contributing impactful solutions that improve healthcare systems and advance patient safety worldwide.

Profiles: Scopus | ORCID

Featured Publications

1. Eizadi-Mood, N., Barzam, E., Pirali, Z., Feizi, A., Namvar, M., Abdi, E., Mirmoghtadaee, P., Mehrpour, O., & Meamar, R. (2025). Gender differences in opioid and stimulant poisoning in the central region of Iran: A cross-sectional study. Scientific Reports.

2. Amrollahi-Sharifabadi, M., Oladejo, T. O., Ibrahim, A. S., Shakoor, B., Mehrpour, O., Sadeghi-Hashjin, G., & Gonçalves, S. (2025). Melatonin’s paradox: From therapeutic benefits to toxicity warnings. Chemico-Biological Interactions, 111556.

3. Kooshki, A., Mansouri, B., Farmani, R., Amirabadizadeh, A., Mehrpour, O., Sanjari, M. J., & Nakhaee, S. (2024). Essential and toxic metal concentrations in biological samples of multiple sclerosis patients: A systematic review and meta-analysis. PLOS ONE, 19(12), e0313851.

4. Mehrpour, O., & Sadeghi, M. (2024). The occurrence of unusually cold weather could contribute to the incidence of carbon monoxide poisoning. Clinical and Experimental Emergency Medicine.

5. Nakhaee, S., Kooshki, A., Hormozi, A., Akbari, A., Mehrpour, O., & Farrokhfall, K. (2023). Cinnamon and cognitive function: A systematic review of preclinical and clinical studies. Nutritional Neuroscience.

Ismaeil Haririan | Pharmaceutical Biomaterials | Outstanding Scientist Award

Published on by World Science Awards

Prof. Ismaeil Haririan | Pharmaceutical Biomaterials | Outstanding Scientist Award

Teharn University of Medical Sciences (TUMS), Iran

Prof. Ismaeil Haririan is a distinguished Professor of Pharmaceutics and Pharmaceutical Biomaterials at the Faculty of Pharmacy, Tehran University of Medical Sciences (TUMS), where he also serves as the Founder of the Department of Pharmaceutical Biomaterials and Head of the Biomaterials Research Center. He earned his Pharm.D. from Tabriz University and pursued a Ph.D. in Pharmaceutics at the University of London in 1993, followed by postdoctoral research in targeted drug delivery, which laid the foundation for his lifelong contributions to biomaterials and regenerative medicine. With over three decades of academic and research experience, Prof. Haririan has played a pioneering role in advancing interdisciplinary research that integrates pharmacy, materials science, and biomedical engineering. His research interests span the design of hyaluronic acid hydrogels for bone and cartilage regeneration, 3D pharming and bioprinting, microfluidics in pharmaceutical applications, drug delivery systems, nanomedicine, and pharmaceutical rheology. He has authored more than 120 SCI-indexed articles, earning over 3,600 citations, an h-index of 34, and an i10-index of 65, reflecting the global impact of his work. His research skills extend across tissue engineering, drug delivery system design, nanostructure characterization, and translational medicine, complemented by his strong expertise in mentoring doctoral candidates and industrial trainees. Recognized internationally as a leading figure in pharmaceutical biomaterials, Prof. Haririan has received numerous awards and honors, including recognition as a world leader in bioprinting research between 2022 and 2025. Beyond his scholarly contributions, he has served in editorial capacities, led major research collaborations, and advanced education by supervising Pharm.D. and Ph.D. students. In conclusion, Prof. Haririan embodies academic excellence, visionary leadership, and innovative research, making him one of the most influential scientists in pharmaceutics and biomaterials whose work continues to inspire progress in regenerative medicine and pharmaceutical sciences worldwide.

Profile: Scopus | ORCID

Featured Publications

Al-Jawadri, A. M. H., Karami, Z., Haririan, I., Akrami, M., & Gholami, M. (2025). Development of a bio-inspired phagocytic stable nanoghost with anti-inflammatory properties for management of inflammation in ulcerative colitis. Journal of Drug Targeting, 33(7), 1-15.

Safari, F., Goudarzi, A., Abolghasemi, H., Mohammad, H. A., Akrami, M., Mohammadi, S., & Haririan, I. (2025). Additive manufacturing of regorafenib tablets: Formulation strategies and characterization for colorectal cancer. Polymers, 17(17), 2302.

Sohrabi, R., Miri, A. H., Rad-Malekshahi, M., Saadatpour, F., Pourjabbar, B., Keshel, S. H., Arefian, E., Balalaei, S., Masoumi, A., Khalili, F., Haririan, I., Akrami, M., & Shahriari, M. H. (2025). Corrigendum to “Development of silk fibroin/collagen film containing GI-20 peptide-loaded PLGA nanoparticles against corneal herpes simplex virus-1” [International Journal of Pharmaceutics, 669 (2025), 125022]. International Journal of Pharmaceutics, 674, 125369.

Torabi, M., Haririan, I., Foroumadi, A., Ghanbari, H., & Ghasemi, F. (2024). A deep learning model based on the BERT pre-trained model to predict the antiproliferative activity of anti-cancer chemical compounds. SAR and QSAR in Environmental Research, 35(11), 971-992

Sa Xiao | Pharmaceutical Science | Best Researcher Award

Published on by World Science Awards

Dr. Sa Xiao | Pharmaceutical Science | Best Researcher Award

Chief Pharmacist, Clinical pharmacist from The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, China

Sa Xiao is an experienced Clinical Pharmacist currently working at the Department of Pharmacy, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong, China. she has dedicated her career to clinical pharmacy with a focus on providing quality patient care and optimizing pharmaceutical practices. Sa Xiao holds a Master’s degree in Pharmacology and a Bachelor’s degree in Pharmaceutical Engineering. Over the past five years and seven months, she has consistently contributed to clinical pharmacy, focusing on improving therapeutic outcomes and pharmaceutical interventions. Sa Xiao’s role places her at the intersection of clinical application and pharmaceutical research, where she works to enhance drug therapy effectiveness and patient safety. Her work contributes directly to hospital-based pharmaceutical care and supports interdisciplinary collaboration in medical settings. Sa Xiao’s background equips her with both theoretical knowledge and practical clinical experience, positioning her as a valuable asset in the healthcare system. While her current profile emphasizes her clinical expertise, expanding her research portfolio could further elevate her impact in the pharmaceutical field. Her dedication, professional growth, and potential for further research contributions make her a promising candidate for recognition in her domain.

Professional Profile

Education

Sa Xiao has built a strong academic foundation that supports her professional excellence in clinical pharmacy. She began her higher education journey at Huzhou Normal University, where she pursued a Bachelor’s degree in Pharmaceutical Engineering from September 2012 to June 2016. This program provided her with essential knowledge of pharmaceutical sciences, drug formulation, and pharmaceutical manufacturing processes. Her education at this stage focused on understanding drug properties, production, and the basic principles that guide pharmaceutical development. After completing her undergraduate studies, Sa Xiao advanced her academic qualifications by enrolling in Guangdong Medical University, where she earned her Master’s degree in Pharmacology from September 2016 to June 2019. This graduate program allowed her to delve deeper into the study of drug actions, mechanisms, and pharmacokinetics. Through her Master’s studies, she developed a comprehensive understanding of clinical pharmacology, which now directly supports her work as a clinical pharmacist. Both her degrees are recognized by the Ministry of Education, China, affirming the academic rigor and credibility of her educational background. Her academic journey demonstrates a seamless transition from pharmaceutical engineering to clinical application, providing her with the necessary expertise to excel in both pharmaceutical sciences and patient-centered clinical practice.

Professional Experience

Sa Xiao has gained substantial professional experience as a Clinical Pharmacist, holding this role since July 2019 at the Department of Pharmacy, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology. With over five years of experience, she has developed a deep understanding of clinical pharmacy operations, patient care protocols, and hospital pharmaceutical services. Her responsibilities likely include reviewing prescriptions, optimizing medication therapies, ensuring the safe and effective use of drugs, and collaborating with medical teams to enhance patient outcomes. Working in a hospital affiliated with a reputable university has provided her with exposure to clinical research, medical education, and interdisciplinary cooperation. Sa Xiao’s experience is not limited to routine pharmacy tasks; her role also requires ongoing learning and adaptation to the latest pharmaceutical guidelines and therapeutic advancements. Her career has been characterized by dedication to improving patient care and supporting evidence-based clinical decisions. While her profile currently focuses on clinical responsibilities, there is potential for her to expand her contributions to include scientific publications, research studies, and leadership in pharmaceutical innovations. Her professional track record reflects commitment, consistency, and the ability to thrive in a demanding healthcare environment.

Research Interest

Sa Xiao’s research interests are rooted in clinical pharmacy and pharmacology, with a focus on optimizing drug therapies, enhancing patient safety, and improving pharmaceutical care within hospital settings. Her academic and professional background suggests a strong interest in therapeutic drug monitoring, drug interactions, and evidence-based medication management. She is likely driven to explore methods for improving the clinical efficacy of pharmacological treatments and minimizing adverse drug reactions. Additionally, she may be interested in research concerning personalized medicine, dosage adjustments for specific patient populations, and clinical outcomes related to pharmaceutical interventions. Her experience as a clinical pharmacist positions her to contribute valuable insights into hospital-based drug management, prescription review processes, and the practical challenges faced in clinical settings. Future research could also include comparative studies on the effectiveness of different pharmacological treatments and the implementation of clinical pharmacy protocols to improve patient care. By aligning her clinical expertise with focused research initiatives, Sa Xiao has the potential to contribute to both national and international discussions in the field of clinical pharmacology and pharmacy practice. Expanding her research interests to cover these areas would significantly strengthen her academic and professional profile.

Research Skills

Sa Xiao possesses a range of research skills that align with her clinical pharmacy background. Her academic training in pharmacology provided her with expertise in drug action mechanisms, pharmacokinetics, and pharmacodynamics, which are essential for conducting clinical pharmaceutical research. She likely has experience in analyzing clinical data, reviewing case studies, and evaluating therapeutic outcomes in real-world settings. Her role as a clinical pharmacist has refined her skills in prescription auditing, patient counseling, and drug therapy evaluation, which contribute to her ability to design practical, patient-focused research projects. Sa Xiao is also expected to be proficient in using clinical databases, medical literature review systems, and pharmacovigilance tools to support her clinical decision-making and potential research activities. Moreover, she may have developed collaborative skills through working with interdisciplinary teams, which are critical for conducting joint clinical studies and implementing hospital-wide pharmaceutical protocols. To further enhance her research portfolio, acquiring advanced skills in statistical analysis, research methodology, and scientific writing would be beneficial. By building on her current skill set and actively participating in research dissemination through conferences and publications, Sa Xiao can establish herself as a leading contributor in the clinical pharmacy research community.

Awards and Honors

At present, no specific awards or honors have been provided for Sa Xiao. However, her sustained commitment to clinical pharmacy over a period of more than five years at a leading university hospital reflects her professional reliability and growing expertise. Although formal recognitions such as research awards, clinical excellence distinctions, or academic honors have not yet been documented, Sa Xiao’s continuous role in a competitive healthcare environment signifies institutional trust in her capabilities. It is possible that she has received internal recognition for her contributions to patient care, medication management, or quality improvement initiatives within her department. Engaging in national or international pharmaceutical competitions, participating in recognized clinical research projects, and contributing to peer-reviewed publications could open avenues for future awards and honors. Earning formal recognition would not only validate her contributions but also help strengthen her professional profile for broader scientific and clinical acknowledgment. Sa Xiao’s consistent career growth and practical impact within the hospital setting suggest that she is well-positioned to achieve significant honors as she continues to expand her involvement in clinical research and professional development activities in the future.

Conclusion

In conclusion, Sa Xiao is a highly capable clinical pharmacist with a strong educational background and valuable experience in the hospital pharmaceutical sector. Her work at The Sixth Affiliated Hospital, School of Medicine, South China University of Technology demonstrates her ability to apply pharmacological knowledge in a clinical environment, directly benefiting patient care and therapeutic practices. While her current profile is predominantly clinical, there is significant potential for her to make substantial research contributions to the field of clinical pharmacy and pharmacology. Sa Xiao’s foundation in pharmaceutical engineering and pharmacology equips her with both theoretical and practical expertise, which can be further advanced through scientific publications, conference presentations, and research collaborations. By actively participating in research dissemination and seeking broader recognition through professional awards, she can enhance her influence within the scientific and medical communities. Sa Xiao’s dedication, clinical precision, and future research potential position her as an emerging contributor to the advancement of pharmaceutical care and clinical pharmacy research. With further academic engagement and research output, she is likely to achieve greater professional recognition and make impactful contributions to the global healthcare landscape.

Publications Top Notes

1. Depression and Suicide/Self-Injury Signals for Weight Loss Medications: A Disproportionality Analysis of Semaglutide, Liraglutide, and Tirzepatide in FAERS Database

  • Journal: Journal of Affective Disorders

  • Publication Date: 2025-06-14

  • Authors: Wang M, Yang Z, Yan M, Liu S, Xiao S

2. Protective Effects of Aqueous Extract of Wampee Fruit Against Anti-Tubercular Drug-Induced Hepatotoxicity in Rats

  • Journal: Journal of Biological Regulators and Homeostatic Agents

  • Publication Date: 2019-01-01

  • Authors: Guan TM, Xiao S, Liu DC, Liao XH, Li WD, Wu KF, Huang R

 

Amir Abaas Momtazi-Borojeni | Biotechnology | Best Researcher Award

Published on by World Science Awards

Assist. Prof. Dr. Amir Abaas Momtazi-Borojeni | Biotechnology | Best Researcher Award

Faculty Member from Neyshabur university of medical sciences, Iran

Dr. Amir Abbas Momtazi-Borojeni is an Assistant Professor of Medical Biotechnology at Neyshabur University of Medical Sciences in Iran. Born on September 17, 1985, in Isfahan, Iran, he has established a distinguished career in medical biotechnology, focusing on nanomedicine, immunotherapy, and phytomedicine. With over 160 publications and more than 7,000 citations, his research has significantly contributed to the fields of cardiovascular and metabolic diseases. His work on PCSK9-targeted therapies and nanoliposomal drug delivery systems has been recognized internationally. Dr. Momtazi-Borojeni’s interdisciplinary approach integrates molecular biology, pharmacology, and bioinformatics, reflecting his commitment to advancing medical science through innovative research.

Professional Profile​

Education

Dr. Momtazi-Borojeni’s academic journey began with a BSc in Biology from Isfahan University (2004–2008), followed by an MSc in Microbial Biotechnology from the same institution (2008–2010). He then pursued a Ph.D. in Medical Biotechnology at Mashhad University of Medical Sciences (2013–2019), where his research focused on developing nanoliposome-based vaccines targeting PCSK9 for lipid-lowering and anti-atherosclerotic effects. His doctoral work combined immunology, nanotechnology, and cardiovascular research, laying the foundation for his future contributions to medical biotechnology.​

Professional Experience

Dr. Momtazi-Borojeni has held various research and academic positions, including roles as a genomics lab expert at the Biotechnology Research Institute in Esfahan and as a part-time researcher at the Pharmaceutical Sciences Research Center of Isfahan University of Medical Sciences. He has also taught courses in cellular and molecular biology, genetic engineering, and bioinformatics at Isfahan University and Islamic Azad University, Neyshabur branch. Currently, he serves as an Assistant Professor at Neyshabur University of Medical Sciences, where he continues to advance research in medical biotechnology.​

Research Interests

Dr. Momtazi-Borojeni’s research interests encompass nanomedicine, immunotherapy, and phytomedicine, with a particular focus on developing innovative treatments for cardiovascular and metabolic diseases. His work on PCSK9-targeted therapies, including vaccine development and siRNA delivery systems, aims to provide alternative strategies for managing hypercholesterolemia and atherosclerosis. Additionally, he explores the therapeutic potential of natural compounds and bioinformatics approaches to identify novel drug targets and understand disease mechanisms.​

Research Skills

Dr. Momtazi-Borojeni possesses a diverse skill set that includes expertise in nanotechnology-based drug delivery, molecular biology techniques, immunological assays, and bioinformatics analysis. His proficiency in designing and characterizing nanoliposomes, conducting in vivo studies, and analyzing gene expression profiles enables him to undertake complex research projects that bridge multiple disciplines. His collaborative work with international researchers further demonstrates his ability to contribute to multidisciplinary teams and advance scientific knowledge.​

Awards and Honors

While specific awards and honors are not detailed in the provided information, Dr. Momtazi-Borojeni’s extensive publication record and citation metrics reflect his significant impact on the field of medical biotechnology. His research has been published in reputable journals, and his contributions to the development of PCSK9-targeted therapies have garnered international recognition. His active participation in scientific communities and collaborations with researchers worldwide underscore his commitment to advancing medical science.​

Conclusion

Dr. Amir Abbas Momtazi-Borojeni’s extensive research in medical biotechnology, particularly in the areas of nanomedicine and immunotherapy, positions him as a strong candidate for the Best Researcher Award. His innovative approaches to treating cardiovascular and metabolic diseases, combined with his interdisciplinary expertise and collaborative spirit, have significantly advanced the field. While specific awards and honors are not listed, his prolific publication record and international collaborations attest to his contributions to medical science. Continued support for his research endeavors will likely yield further breakthroughs in therapeutic strategies and enhance our understanding of complex diseases.​

Publications Top Notes

  1. Therapeutic effects of curcumin in inflammatory and immune‐mediated diseases: A nature‐made jack‐of‐all‐trades?

    • Authors: E. Abdollahi, A.A. Momtazi, T.P. Johnston, A. Sahebkar

    • Year: 2018

    • Citations: 302

  2. Effects of curcuminoids plus piperine on glycemic, hepatic and inflammatory biomarkers in patients with type 2 diabetes mellitus: a randomized double-blind placebo-controlled trial

    • Authors: Y. Panahi, N. Khalili, E. Sahebi, S. Namazi, L.E. Simental-Mendía, M. Majeed, A. Sahebkar

    • Year: 2018

    • Citations: 257

  3. Curcumin as a MicroRNA regulator in cancer: a review

    • Authors: A.A. Momtazi, F. Shahabipour, S. Khatibi, T.P. Johnston, M. Pirro, A. Sahebkar

    • Year: 2016

    • Citations: 256

  4. Curcumin: A natural modulator of immune cells in systemic lupus erythematosus

    • Authors: A.A. Momtazi-Borojeni, S.M. Haftcheshmeh, S.A. Esmaeili, T.P. Johnston, A. Sahebkar

    • Year: 2018

    • Citations: 233

  5. Isolation, identification, and characterization of cancer stem cells: A review

    • Authors: M.R. Abbaszadegan, V. Bagheri, M.S. Razavi, A.A. Momtazi, A. Sahebkar

    • Year: 2017

    • Citations: 228

  6. Curcumin: a potentially powerful tool to reverse cisplatin-induced toxicity

    • Authors: R. Rezaee, A.A. Momtazi, A. Monemi, A. Sahebkar

    • Year: 2017

    • Citations: 199

  7. Cardioprotective microRNAs: Lessons from stem cell-derived exosomal microRNAs to treat cardiovascular disease

    • Authors: A.S. Moghaddam, J.T. Afshari, S.A. Esmaeili, E. Saburi, Z. Joneidi, A. Sahebkar

    • Year: 2019

    • Citations: 196

  8. A review on the pharmacology and toxicology of steviol glycosides extracted from Stevia rebaudiana

    • Authors: A. Abbas Momtazi-Borojeni, S.A. Esmaeili, E. Abdollahi, A. Sahebkar

    • Year: 2017

    • Citations: 192

  9. Role of microRNAs in the therapeutic effects of curcumin in non-cancer diseases

    • Authors: A.A. Momtazi, G. Derosa, P. Maffioli, M. Banach, A. Sahebkar

    • Year: 2016

    • Citations: 186

  10. Difluorinated curcumin: A promising curcumin analogue with improved anti-tumor activity and pharmacokinetic profile

    • Authors: A. Abbas Momtazi, A. Sahebkar

    • Year: 2016

    • Citations: 178

Yi-Ping Huang | Pharmaceutical Science | Women Researcher Award

Published on by World Science Awards

Assoc. Prof. Dr. Yi-Ping Huang | Pharmaceutical Science | Women Researcher Award

Associate Professor from Department of Physiology, China Medical University, Taiwan

Yi-Ping Huang is an accomplished Associate Professor in the Department of Physiology at China Medical University, with over 32 years of experience in both teaching and research. His primary focus is on cancer treatment, specifically investigating the therapeutic effects of natural and synthetic compounds on cancer cells. Over the years, Huang has significantly contributed to the field, publishing numerous peer-reviewed articles and advancing the understanding of cancer treatment mechanisms, particularly apoptosis, DNA damage, and anti-metastasis pathways. His expertise extends to drug synergy, especially in combination with chemotherapy. He has also been involved in teaching innovations in physiology, emphasizing student engagement and educational research. Huang’s extensive research output and leadership in the field have made him a well-respected figure in the scientific community, as reflected in his numerous research projects and academic publications.

Professional Profile

Education

Yi-Ping Huang completed his undergraduate studies in Physiology at Yang-Ming University, laying the foundation for his extensive career in research and academia. His academic journey provided a strong base for his research into cancer treatment and physiological mechanisms. This solid educational background enabled Huang to develop expertise in a range of specialized topics, particularly in the therapeutic effects of natural compounds. Over the years, his continuous learning and commitment to his field have propelled his success, making him an established academic in the study of cancer therapy and physiology.

Professional Experience

Yi-Ping Huang has a long and distinguished career in both academia and research. As an Associate Professor at China Medical University, he has been instrumental in educating students and conducting cutting-edge research on cancer therapy. With over three decades of experience, Huang has led numerous research projects focusing on natural and synthetic compounds in cancer treatment. His role also includes teaching and mentoring students, guiding them in the latest scientific advancements. Huang’s professional experience is marked by extensive publications in high-impact journals, further showcasing his contributions to the scientific community and his leadership in advancing cancer research.

Research Interests

Yi-Ping Huang’s primary research interests revolve around the use of natural and synthetic compounds in cancer therapy. His work explores the mechanisms through which these compounds induce apoptosis, DNA damage, and inhibit metastasis in cancer cells. Huang is particularly focused on understanding how these compounds can synergize with chemotherapy drugs to overcome resistance and improve treatment outcomes. His ongoing research also investigates the therapeutic effects of compounds such as Demethoxycurcumin (DMC), Phenethyl Isothiocyanate (PEITC), and PW06 in various cancer types, including glioblastoma and colon cancer. These areas of interest align with his goal of advancing cancer therapy through the identification and development of novel therapeutic agents.

Research Skills

Yi-Ping Huang’s research skills are extensive and diverse, ranging from molecular biology techniques to cancer therapy research. He possesses a deep understanding of cancer cell biology, particularly in apoptosis, DNA repair, and metastasis inhibition. Huang has demonstrated proficiency in the use of various experimental models to study the effects of natural and synthetic compounds on cancer cells, including in vitro and in vivo models. His expertise extends to studying drug interactions and mechanisms of drug resistance, especially in relation to chemotherapy. Huang’s interdisciplinary approach to research, combining pharmacology, molecular biology, and cancer therapy, has led to groundbreaking studies that have contributed significantly to the field.

Awards and Honors

Throughout his illustrious career, Yi-Ping Huang has received numerous awards and honors that recognize his contributions to the scientific community. His groundbreaking research in cancer therapy, particularly in the use of natural and synthetic compounds, has earned him accolades from academic institutions and scientific organizations. Huang’s work on compounds such as Demethoxycurcumin and Phenethyl Isothiocyanate has been widely recognized in the field of oncology research. His consistent contributions to cancer treatment research and his leadership in academia have earned him recognition as a leading expert in his field, enhancing his reputation as an influential figure in cancer research.

Conclusion

Yi-Ping Huang’s career has been defined by significant contributions to cancer research, particularly in the development and understanding of natural and synthetic compounds as therapeutic agents. His research focuses on the molecular mechanisms of apoptosis, DNA damage, and anti-metastasis, offering potential for groundbreaking advancements in cancer treatment. With over three decades of experience, Huang’s work continues to influence both basic and clinical cancer research. His leadership in academia, coupled with his innovative research, positions him as a respected figure in the scientific community. As he continues to push the boundaries of cancer therapy, his contributions are likely to have a lasting impact on the field.

Publication Top Notes

M084 causes cell cycle arrest and inhibits voltage-gated Na⁺ and K⁺ channels in neuronal N2A cells
Authors: Iat Lon Leong, Chinmin Chuang, Chenghsun Wu, Yukman Leung, Yiping Huang
Year: 2025

2. MCU-i4, a mitochondrial Ca²⁺ uniporter modulator, induces breast cancer BT474 cell death by enhancing glycolysis, ATP production and reactive oxygen species (ROS) burst
Authors: Edmund Cheung So, Louis Wing Cheong Chow, Chinmin Chuang, Yukman Leung, Yiping Huang
Year: 2025

3. Physalin A induces apoptosis through conjugating with Fas-FADD cell death receptor in human oral squamous carcinoma cells and suppresses HSC-3 cell xenograft tumors in NOD/SCID mice
Authors: Fu Shin Chueh, Shengyao Hsu, Kuangchi Lai, Yiping Huang, Wen Tsong Hsieh
Year: 2025

4. PEITC Induces DNA Damage and Inhibits DNA Repair-Associated Proteins in Human Retinoblastoma Cells In Vitro
Authors: Shengyao Hsu, Yiping Huang, Techun Hsia, Fu Shin Chueh, Chaolin Kuo
Year: 2024

5. Armillaria mellea Mycelia Alleviate PM2.5-Induced Pulmonary Inflammation in Murine Models
Authors: Yiping Huang, Yutsen Huang, Huiyu Wu, Chinchu Chen, Chih Ho Lai
Year: 2024

6. RAGE participates in the intracellular transport of Campylobacter jejuni cytolethal distending toxin
Authors: Yufang Chang, Yiping Huang, Chiahuei Chou, Chenghsun Chiu, Chih Ho Lai
Year: 2024
Citations: 2

7. PW06 suppresses cancer cell metastasis in human pancreatic carcinoma MIA PaCa-2 cells via the inhibitions of p-Akt/mTOR/NF-κB and MMP2/MMP9 signaling pathways in vitro
Authors: Yiping Huang, Chunan Yeh, Yishih Ma, Jin Cherng Lien, Wen Tsong Hsieh
Year: 2024
Citations: 2

Niclas Nikolai Stephanson | Pharmaceutical Science | Best Researcher Award

Published on by World Science Awards

Mr. Niclas Nikolai Stephanson | Pharmaceutical Science | Best Researcher Award

Scientist from Karolinska University Hospital, Sweden

Niclas Nikolai Stephanson is a seasoned clinical pharmacologist and forensic chemist based at the Karolinska University Hospital in Stockholm, Sweden. With a career spanning over three decades, he has carved out a notable reputation in the scientific community, particularly in the analysis of drugs of abuse. Holding a PhD in Medicine from the prestigious Karolinska Institutet, he combines academic rigor with practical experience. Niclas is a licensed pharmacist, senior chemist, and prolific researcher whose contributions include over 35 peer-reviewed scientific publications. His research focus lies at the intersection of pharmacology and toxicology, with a specialization in mass spectrometry and method development for detecting drugs in biological materials. He plays a pivotal role in improving clinical and forensic diagnostics through enhanced analytical techniques. Niclas’s work has contributed to better accuracy in detecting and quantifying illicit and therapeutic drugs, ultimately supporting public health and justice systems. His long-standing association with one of Europe’s most reputable hospitals is a testament to his dedication, expertise, and continuous contribution to the advancement of clinical pharmacology. Stephanson stands out not only for his technical skills but also for his impactful research that bridges laboratory science with real-world applications in healthcare and law enforcement.

Professional Profile

Education

Niclas Nikolai Stephanson received his academic training at the renowned Karolinska Institutet in Stockholm, Sweden, where he earned his PhD in Medicine in 2007. His doctoral work was rooted in the Department of Medicine and focused on the interdisciplinary field of clinical pharmacology, an area combining pharmacokinetics, pharmacodynamics, and toxicology. Prior to his doctoral studies, Niclas qualified as a licensed pharmacist, which provided him with a strong foundation in pharmaceutical sciences, drug interactions, and patient-centered pharmacotherapy. His dual academic background in pharmacy and medicine positions him at the nexus of research and clinical practice. This educational pathway has enabled him to integrate principles of chemistry, biology, and medicine in his professional work. Niclas’s academic experience at Karolinska Institutet—a globally respected institution known for its role in awarding the Nobel Prize in Physiology or Medicine—further highlights the high standards and intellectual rigor of his training. The comprehensive and multidisciplinary nature of his education has empowered him to design and conduct advanced analytical research while maintaining a deep understanding of clinical implications. Overall, his educational background has significantly influenced his ability to carry out complex method development and toxicological investigations with precision and clinical relevance.

Professional Experience

Niclas Nikolai Stephanson has been professionally affiliated with Karolinska University Hospital in Stockholm since August 1992, where he currently holds the position of Senior Chemist in the Department of Clinical Pharmacology. Over the span of more than three decades, he has contributed significantly to the hospital’s mission of delivering cutting-edge clinical diagnostics and therapeutic monitoring. As a licensed pharmacist and senior forensic chemist, Niclas has specialized in the analysis of drugs of abuse, playing a key role in the development and implementation of advanced analytical techniques for routine and investigational use. His daily responsibilities involve overseeing laboratory operations, mentoring junior staff, and collaborating with clinicians to interpret toxicological results. His long tenure reflects not only technical proficiency but also institutional trust in his expertise and leadership. Working within a hospital setting, he has consistently ensured that his research aligns with real-world clinical demands, particularly in the identification and quantification of illicit substances and medications in complex biological matrices. Stephanson’s role at Karolinska University Hospital also supports legal and forensic proceedings, as accurate drug analysis is crucial for both medical and judicial outcomes. His professional experience highlights a unique blend of scientific inquiry, clinical application, and public health impact.

Research Interests

Niclas Nikolai Stephanson’s research interests are centered on clinical pharmacology, forensic toxicology, and analytical chemistry, with a particular focus on the detection and analysis of drugs of abuse. He is especially committed to method development in toxicological screening, applying advanced techniques such as mass spectrometry to improve the precision and sensitivity of drug detection. His work often explores various biological matrices—ranging from blood and urine to less conventional materials like hair or oral fluid—to assess the presence and metabolism of illicit and therapeutic substances. Niclas’s interest in mass spectrometry enables the high-resolution identification of complex compounds, which is critical for timely and accurate diagnoses in both clinical and forensic settings. He is also interested in validating new protocols for routine use in healthcare facilities, aiming to bridge the gap between research and clinical practice. Additionally, his work contributes to public safety by improving methodologies used in legal and judicial drug testing. Through collaborations and internal projects at Karolinska University Hospital, his research continues to evolve in response to emerging substances and new analytical challenges. Overall, his interests reflect a strong alignment with societal needs in healthcare and law enforcement, emphasizing both scientific innovation and practical application.

Research Skills

Niclas Nikolai Stephanson possesses a robust set of research skills that underscore his success as a senior clinical chemist and academic contributor. One of his core strengths lies in advanced method development, particularly in the field of forensic toxicology, where he designs, tests, and refines techniques for detecting drugs of abuse in biological matrices. His proficiency in mass spectrometry—including LC-MS/MS and GC-MS systems—is central to his work, enabling precise identification and quantification of substances even in trace amounts. Niclas is also skilled in biological sample preparation, including extraction and purification techniques that are critical for ensuring reliable analytical results. He demonstrates strong data analysis and validation abilities, ensuring that his methods meet rigorous standards for reproducibility, sensitivity, and specificity. In addition, he has experience in regulatory compliance and quality assurance, ensuring that laboratory practices align with healthcare and forensic standards. His skill set extends to scientific writing and publication, as evidenced by his record of more than 35 peer-reviewed articles. These competencies, combined with his practical knowledge of clinical workflows, empower him to translate complex research into diagnostic and therapeutic tools. His research skills are not only technical but also strategic, aiming to meet real-world challenges with innovative scientific solutions.

Awards and Honors

Although specific awards or honors for Niclas Nikolai Stephanson are not explicitly listed, his sustained position at Karolinska University Hospital and the volume of his peer-reviewed publications are indicative of high professional recognition and esteem. Holding a senior chemist position at one of Europe’s leading medical institutions is a reflection of both his expertise and institutional trust in his abilities. His role in the department of Clinical Pharmacology implies consistent recognition through internal appointments, research responsibilities, and possibly departmental accolades for contributions to method development and toxicological analysis. Publishing over 35 scientific articles in peer-reviewed journals also suggests peer recognition and validation of his work within the scientific community. It is not uncommon in the medical sciences for researchers with such a track record to be involved in national and international working groups or to serve as peer reviewers or advisors in forensic and clinical pharmacology. His continued association with the Karolinska Institutet—home to Nobel-level research—implies a professional standing that exceeds routine recognition. While specific honors may not be documented publicly, his contributions and career longevity highlight a professional trajectory marked by consistent achievement and expert-level contribution to clinical science.

Conclusion

Niclas Nikolai Stephanson stands as a highly accomplished clinical pharmacologist and forensic chemist whose contributions span research, diagnostics, and public health. His work at Karolinska University Hospital since 1992, combined with a PhD from Karolinska Institutet, demonstrates a career dedicated to scientific excellence and societal impact. He has specialized in the development of analytical methods using mass spectrometry to detect drugs of abuse, contributing to over 35 peer-reviewed publications. His research not only enhances clinical decision-making but also supports forensic and legal systems by ensuring accurate and timely drug testing. While his achievements are impressive, expanding his international collaborations and diversifying his research themes could further amplify his academic influence. Nonetheless, his sustained excellence and deep specialization in clinical pharmacology make him a valuable asset to the scientific and medical community. Stephanson’s profile exemplifies the rare blend of research depth, clinical utility, and long-term dedication, positioning him as a strong candidate for prestigious honors such as the Best Researcher Award. His work bridges the gap between bench science and bedside application, marking him as a leader in toxicological innovation and a model for aspiring researchers in the field.

Publications Top Notes

  1. Title: Application of liquid chromatography combined with high resolution mass spectrometry for urine drug testing
    Authors: O.M.L. Beck (Olof M.L.), A. Rylski (Alexia), N.N. Stephanson (Nikolai N.)
    Citations: 4

  2. Title: Use of LC–HRMS in full scan-XIC mode for multi-analyte urine drug testing – a step towards a ‘black-box’ solution?
    Authors: N.N. Stephanson (Nikolai N.), P. Signell (Patrick), A. Helander (Anders), O.M.L. Beck (Olof M.L.)
    Year: 2017
    Citations: 19